Scaffold-mediated switching of lymphoma metabolism in culture

Bhatt, Rachana; Ravi, Dashnamoorthy; Evens, Andrew M.; Parekkadan, Biju

doi:10.1186/s40170-022-00291-y

Cited by 6 publications

(2 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5A). Despite being a non-enzymatic cell harvesting solution frequented with VitroGel platforms [33, 34] Cell Recovery Solution alone was unable to reconstitute MSCs into single-cell suspension potentially due to encapsulated MSCs achieving a high density and extracellular network within VitroGel-MSC microcapsules. After 30 min of digestion, 83% ± 7% of VitroGel-MSC microcapsules remained non-degraded (Fig.…”

Section: Resultsmentioning

confidence: 99%

3D Microcapsules for Human Bone Marrow Derived Mesenchymal Stem Cell Biomanufacturing in a Vertical-Wheel Bioreactor

Teryek

Jadhav

Bento

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Microencapsulation of human mesenchymal stromal cells (MSCs) via electrospraying has been well documented in tissue engineering and regenerative medicine. Herein, we report the use of microencapsulation, via electrospraying, for MSC expansion using a commercially available hydrogel that is durable, optimized to MSC culture, and enzymatically degradable for cell recovery. Critical parameters of the electrospraying encapsulation process such as seeding density, correlation of microcapsule output with hydrogel volume, and applied voltage were characterized to consistently fabricate cell-laden microcapsules of uniform size. Upon encapsulation, we then verified ~ 10x expansion of encapsulated MSCs within a vertical-wheel bioreactor and the preservation of critical quality attributes such as immunophenotype and multipotency after expansion and cell recovery. Finally, we highlight the genetic manipulation of encapsulated MSCs as an example of incorporating bioactive agents in the capsule material to create new compositions of MSCs with altered phenotypes.

show abstract

Section: Resultsmentioning

confidence: 99%

3D Microcapsules for Human Bone Marrow Derived Mesenchymal Stem Cell Biomanufacturing in a Vertical-Wheel Bioreactor

Teryek

Jadhav

Bento

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, no small-molecule inhibitor targeting the MYC gene is currently tested in clinical trials. Recently, Bhatt et al cultured DLBCL cells in three-dimensional matrices and discovered a reduced proliferative activity and altered metabolism that is consistent with in vivo tumor cell function [ 233 ]. Development of three-dimensional conditions that stabilize tumor cell function towards in vivo phenotype might be helpful for the understanding of lymphoma metabolic process and make progress in relevant research.…”

Section: Therapeutic Strategies Targeting Metabolismmentioning

confidence: 99%

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma

Pang

Xu-Monette

et al. 2023

IJMS

View full text Add to dashboard Cite

Lymphoma is a heterogeneous group of diseases that often require their metabolism program to fulfill the demand of cell proliferation. Features of metabolism in lymphoma cells include high glucose uptake, deregulated expression of enzymes related to glycolysis, dual capacity for glycolytic and oxidative metabolism, elevated glutamine metabolism, and fatty acid synthesis. These aberrant metabolic changes lead to tumorigenesis, disease progression, and resistance to lymphoma chemotherapy. This metabolic reprogramming, including glucose, nucleic acid, fatty acid, and amino acid metabolism, is a dynamic process caused not only by genetic and epigenetic changes, but also by changes in the microenvironment affected by viral infections. Notably, some critical metabolic enzymes and metabolites may play vital roles in lymphomagenesis and progression. Recent studies have uncovered that metabolic pathways might have clinical impacts on the diagnosis, characterization, and treatment of lymphoma subtypes. However, determining the clinical relevance of biomarkers and therapeutic targets related to lymphoma metabolism is still challenging. In this review, we systematically summarize current studies on metabolism reprogramming in lymphoma, and we mainly focus on disorders of glucose, amino acids, and lipid metabolisms, as well as dysregulation of molecules in metabolic pathways, oncometabolites, and potential metabolic biomarkers. We then discuss strategies directly or indirectly for those potential therapeutic targets. Finally, we prospect the future directions of lymphoma treatment on metabolic reprogramming.

show abstract